Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides

Di Huang,Xiaofeng Zhu,Shuying Ye,Jiahui Zhang,Jianyou Liao,Ning Zhang,Xin Zeng,Jiawen Wang,Bing Yang,Yin Zhang,Liyan Lao,Jianing Chen,Min Xin,Yan Nie,Phei Er Saw,Shicheng Su,Erwei Song

DOI: https://doi.org/10.1038/s41586-023-06834-7

IF: 64.8

2023-12-14

Nature

Abstract:Emerging data have shown that previously defined noncoding genomes might encode peptides that bind human leukocyte antigen (HLA) as cryptic antigens to stimulate adaptive immunity 1,2 . However, the significance and mechanisms of action of cryptic antigens in anti-tumour immunity remain unclear. Here mass spectrometry of the HLA class I (HLA-I) peptidome coupled with ribosome sequencing of human breast cancer samples identified HLA-I-binding cryptic antigenic peptides that were noncanonically translated by a tumour-specific circular RNA (circRNA): circFAM53B. The cryptic peptides efficiently primed naive CD4 + and CD8 + T cells in an antigen-specific manner and induced anti-tumour immunity. Clinically, the expression of circFAM53B and its encoded peptides was associated with substantial infiltration of antigen-specific CD8 + T cells and better survival in patients with breast cancer and patients with melanoma. Mechanistically, circFAM53B-encoded peptides had strong binding affinity to both HLA-I and HLA-II molecules. In vivo, administration of vaccines consisting of tumour-specific circRNA or its encoded peptides in mice bearing breast cancer tumours or melanoma induced enhanced infiltration of tumour-antigen-specific cytotoxic T cells, which led to effective tumour control. Overall, our findings reveal that noncanonical translation of circRNAs can drive efficient anti-tumour immunity, which suggests that vaccination exploiting tumour-specific circRNAs may serve as an immunotherapeutic strategy against malignant tumours.

multidisciplinary sciences